Logo.png
Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects
24 juin 2021 09h30 HE | Oculogica, Inc.
NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without the...
Logo.png
Oculogica Adds to IP Portfolio with Patent for Assessment of Impairment Due to Cannabis
25 mai 2021 10h45 HE | Oculogica, Inc.
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a...
Logo.png
Oculogica Receives Department of Defense Grant to Develop Wearable Concussion Diagnostic with Pre-eminent Partners
18 mai 2021 09h57 HE | Oculogica, Inc.
NEW YORK, May 18, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a...
Oculogica Announces New Category 3 CPT Code Created by American Medical Association
29 oct. 2019 07h45 HE | Oculogica, Inc.
NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics for brain health, announced today that the American Medical Association (AMA) has...
Oculogica Receives FDA Marketing Authorization for EyeBOX®, the First Non-Invasive, Baseline-Free Test for Concussion
03 janv. 2019 07h45 HE | Oculogica, Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics, announced that the U.S. Food and Drug Administration (FDA) granted their De Novo request...